An Open-label Uncontrolled Study to Assess the Safety and Immunogenicity of the Inactivated Adsorbed Vaccine Against COVID-19 (Coronavac) in Individuals Over 18 Years of Age During 24 Months of Follow-up
Latest Information Update: 06 Jul 2023
At a glance
- Drugs SARS-COV-2 vaccine-inactivated-Sinovac-Biotech (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions; Pharmacodynamics
- 06 Jul 2021 Planned primary completion date changed from 1 Jul 2021 to 1 Sep 2021.
- 06 Jul 2021 Status changed from not yet recruiting to active, no longer recruiting.
- 18 Feb 2021 New trial record